Market open
Relay Therapeutics/$RLAY
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Relay Therapeutics
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).
Ticker
$RLAY
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
294
Website
RLAY Metrics
BasicAdvanced
$656M
-
-$2.61
1.67
-
Price and volume
Market cap
$656M
Beta
1.67
52-week high
$11.02
52-week low
$3.50
Average daily volume
2.3M
Financial strength
Current ratio
18.42
Quick ratio
17.876
Long term debt to equity
5.279
Total debt to equity
5.938
Management effectiveness
Return on assets (TTM)
-26.87%
Return on equity (TTM)
-42.69%
Valuation
Price to revenue (TTM)
51.785
Price to book
0.78
Price to tangible book (TTM)
0.78
Price to free cash flow (TTM)
-1.834
Growth
Revenue change (TTM)
-61.22%
Earnings per share change (TTM)
-2.54%
3-year revenue growth (CAGR)
-51.01%
3-year earnings per share growth (CAGR)
-2.74%
What the Analysts think about RLAY
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Relay Therapeutics stock.
RLAY Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
RLAY Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
RLAY News
AllArticlesVideos
Relay Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights on February 26, 2025
GlobeNewsWire·5 days ago
Relay Therapeutics: A Precision Oncology Play Worth The Risk
Seeking Alpha·2 weeks ago
Relay Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Relay Therapeutics stock?
Relay Therapeutics (RLAY) has a market cap of $656M as of February 24, 2025.
What is the P/E ratio for Relay Therapeutics stock?
The price to earnings (P/E) ratio for Relay Therapeutics (RLAY) stock is 0 as of February 24, 2025.
Does Relay Therapeutics stock pay dividends?
No, Relay Therapeutics (RLAY) stock does not pay dividends to its shareholders as of February 24, 2025.
When is the next Relay Therapeutics dividend payment date?
Relay Therapeutics (RLAY) stock does not pay dividends to its shareholders.
What is the beta indicator for Relay Therapeutics?
Relay Therapeutics (RLAY) has a beta rating of 1.67. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.